title: Phase II study of edatrexate in advanced head and neck cancer. A Southwest Oncology Group study.
abstract: Fifty-two patients with persistent, recurrent and/or metastatic squamous cell cancer of the head and neck were treated with weekly edatrexate, 80 mg/m2. Nine patients had received previous adjuvant or neoadjuvant chemotherapy. Of the 46 eligible patients, two complete responses and one partial response were observed (6%, 95% confidence interval of 1-18%). The most common toxicities were myelosuppression and mucositis, but dermatologic toxicity was also observed in 25% of patients. Edatrexate appears to have limited activity in advanced head and neck cancer.
authors.affiliation: Riverside Methodist Hospitals, Columbus, OH, USA.
authors.forename: J P
authors.initials: JP
authors.lastname: Kuebler
authors.forename: J
authors.initials: J
authors.lastname: Benedetti
authors.forename: D E
authors.initials: DE
authors.lastname: Schuller
authors.forename: J
authors.initials: J
authors.lastname: Ensley
authors.forename: S M
authors.initials: SM
authors.lastname: Grunberg
authors.forename: M J
authors.initials: MJ
authors.lastname: Muirhead
authors.forename: K E
authors.initials: KE
authors.lastname: Richert-Boe
authors.forename: M E
authors.initials: ME
authors.lastname: Marshall
mesh_terms: D000328:Adult; D000368:Aged; D000630:Aminopterin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; C040210:edatrexate; D000630:Aminopterin